User login
Dr. Stephen Jones discusses TEAM trial findings that suggest exemestane improves breast cancer survival over tamoxifen at 2.75 years of follow-up. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.
Dr. Stephen Jones discusses TEAM trial findings that suggest exemestane improves breast cancer survival over tamoxifen at 2.75 years of follow-up. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.
Dr. Stephen Jones discusses TEAM trial findings that suggest exemestane improves breast cancer survival over tamoxifen at 2.75 years of follow-up. Kerri Wachter of Elsevier Global Medical News (EGMN) reports from the annual San Antonio Breast Cancer Symposium.